Provenance Wealth Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.3K Buy
154
+146
+1,825% +$12.1K ﹤0.01% 1175
2026
Q2
$539 Buy
+8
New +$533 ﹤0.01% 569
2025
Q2
– Sell
-30
Closed -$2.05K – 458
2025
Q1
$2.05K Hold
30
– – ﹤0.01% 402
2024
Q4
$2.33K Hold
30
– – ﹤0.01% 413
2024
Q3
$2.01K Hold
30
– – ﹤0.01% 461
2024
Q2
$3.4K Hold
30
– – ﹤0.01% 347
2024
Q1
$4.16K Sell
30
-16
-35% -$2.01K ﹤0.01% 362
2023
Q4
$5.71K Buy
46
+16
+53% +$1.64K ﹤0.01% 355
2023
Q3
$2.8K Hold
30
– – ﹤0.01% 294

Other funds holding DXCM

Provenance Wealth Advisors's DXCM Position: Q3 2026 in Review

Provenance Wealth Advisors increased its DexCom (DXCM) stake by 1,825% in Q3 2026, buying an estimated $12.1K and bringing the position to 154 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1175.

Provenance Wealth Advisors first reported a position in DXCM in Q3 2023 and has held it in 9 quarters since. 1,056 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Provenance Wealth Advisors held 154 shares of DexCom worth $13.3K as of Q3 2026.
  • Provenance Wealth Advisors bought 146 DexCom shares in Q3 2026, an estimated $12.1K.
  • DexCom made up ﹤0.01% of Provenance Wealth Advisors's portfolio in Q3 2026, its #1175 holding.
  • Provenance Wealth Advisors first reported a position in DexCom in Q3 2023 and has held it in 9 quarters since.
  • 1,056 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Provenance Wealth Advisors's 13F filing for Q3 2026, filed 30 Oct 2026.